(Q24200991)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23450558%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

meta-analysis

0 references

title

Pre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipients (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23450558%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

0 references

3

Giovanni F M Strippoli

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23450558%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

2

Angela C Webster

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23450558%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

author name string

Daniel S Owers

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23450558%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Kathy Kable

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23450558%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Elisabeth M Hodson

series ordinal

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23450558%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

publication date

28 February 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23450558%20AND%20SRC:MED&resulttype=core&format=json

Cochrane Database of Systematic Reviews

24 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23450558%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23450558%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

page(s)

CD005133

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23450558%20AND%20SRC:MED&resulttype=core&format=json

Prophylaxis followed by preemptive therapy versus preemptive therapy for prevention of human cytomegalovirus disease in pediatric patients undergoing liver transplantation

24 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005133.PUB3

Preemptive oral ganciclovir therapy versus prophylaxis to prevent symptomatic cytomegalovirus infection after kidney transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005133.PUB3

Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005133.PUB3

Impact of prophylactic versus preemptive valganciclovir on long-term renal allograft outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005133.PUB3

Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: results of a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005133.PUB3

Cytomegalovirus pp65 antigen-guided preemptive therapy with ganciclovir in solid organ transplant recipients: a prospective, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005133.PUB3

Preemptive use of oral ganciclovir to prevent cytomegalovirus infection in liver transplant patients: a randomized, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005133.PUB3

Prospective randomized trial to assess the value of preemptive oral therapy for CMV infection following liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005133.PUB3

Long-term outcomes of pre-emptive valganciclovir compared with valacyclovir prophylaxis for prevention of cytomegalovirus in renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005133.PUB3

Intragraft cytomegalovirus infection: a randomized trial of valacyclovir prophylaxis versus pre-emptive therapy in renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005133.PUB3

Pre-emptive therapy of CMVpp65 antigen positive renal transplant recipients with oral ganciclovir: a randomized, comparative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005133.PUB3

Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005133.PUB3

Clinical course of cytomegalovirus (CMV) viremia with and without ganciclovir treatment in CMV-seropositive kidney transplant recipients. Longitudinal follow-up of CMV pp65 antigenemia assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005133.PUB3

Pharmacologic basis for high-dose oral acyclovir prophylaxis of cytomegalovirus disease in renal allograft recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005133.PUB3

Studies evaluating high-dose acyclovir, intravenous immune globulin, and cytomegalovirus hyperimmunoglobulin for prophylaxis against cytomegalovirus in kidney transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005133.PUB3

A comparison of ganciclovir and acyclovir to prevent cytomegalovirus after lung transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005133.PUB3

Valacyclovir prevention of cytomegalovirus reactivation after heart transplantation: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005133.PUB3

Cytomegalovirus infection in simultaneous pancreas-kidney transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005133.PUB3

Cytomegalovirus: occurrence, severity, and effect on graft survival in simultaneous pancreas-kidney transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005133.PUB3

Dosing of intravenous ganciclovir for the prophylaxis and treatment of cytomegalovirus infection in solid organ transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005133.PUB3

Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral Ganciclovir International Transplantation Study Group [corrected].

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005133.PUB3

Human cytomegalovirus pp67 mRNAemia versus pp65 antigenemia for guiding preemptive therapy in heart and lung transplant recipients: a prospective, randomized, controlled, open-label trial1

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005133.PUB3

Comparison of intravenous ganciclovir followed by oral acyclovir with intravenous ganciclovir alone for prevention of cytomegalovirus and Epstein-Barr virus disease after liver transplantation in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005133.PUB3

Recombinant phenotyping of cytomegalovirus sequence variants detected after 200 or 100 days of valganciclovir prophylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005133.PUB3

Response to questions regarding the design and results of the IMPACT trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005133.PUB3

The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005133.PUB3

Extended valganciclovir prophylaxis in D+/R- kidney transplant recipients is associated with long-term reduction in cytomegalovirus disease: two-year results of the IMPACT study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005133.PUB3

IMPACT trial results should not change current standard of care of 100 days for cytomegalovirus prophylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005133.PUB3

Ganciclovir pharmacokinetic parameters do not change when extending valganciclovir cytomegalovirus prophylaxis from 100 to 200 days

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005133.PUB3

Immune globulin versus antivirals versus combination for prevention of cytomegalovirus disease in transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005133.PUB3

Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005133.PUB3

Ganciclovir prophylaxis decreases frequency and severity of cytomegalovirus disease in seropositive liver transplant recipients treated with OKT3 monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005133.PUB3

A randomized, controlled trial comparing ganciclovir to ganciclovir plus foscarnet (each at half dose) for preemptive therapy of cytomegalovirus infection in transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005133.PUB3

A Controlled Trial of Ganciclovir to Prevent Cytomegalovirus Disease after Heart Transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005133.PUB3

Extended valganciclovir prophylaxis to prevent cytomegalovirus after lung transplantation: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005133.PUB3

Absence of cytomegalovirus-resistance mutations after valganciclovir prophylaxis, in a prospective multicenter study of solid-organ transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005133.PUB3

Clinical utility of cytomegalovirus (CMV) serology testing in high-risk CMV D+/R- transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005133.PUB3

Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005133.PUB3

Pharmacokinetic profile of ganciclovir after its oral administration and from its prodrug, valganciclovir, in solid organ transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005133.PUB3

Pharmacodynamics of oral ganciclovir and valganciclovir in solid organ transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005133.PUB3

A randomized, double-blind, pharmacokinetic study of oral maribavir with tacrolimus in stable renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005133.PUB3

Valacyclovir for cytomegalovirus prophylaxis reduces the risk of acute renal allograft rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005133.PUB3

The impact of cytomegalovirus disease and asymptomatic infection on acute renal allograft rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005133.PUB3

Prospective comparison of valacyclovir and oral ganciclovir for prevention of cytomegalovirus disease in high-risk renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005133.PUB3

A randomized prospective controlled trial of oral ganciclovir versus oral valacyclovir for prophylaxis of cytomegalovirus disease after renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005133.PUB3

Cytomegalovirus (CMV) prophylaxis by acyclovir in pre-transplant CMV-positive renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005133.PUB3

The association of viral infection and chronic allograft nephropathy with graft dysfunction after renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005133.PUB3

Impact of prophylactic immediate posttransplant ganciclovir on development of transplant atherosclerosis: a post hoc analysis of a randomized, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005133.PUB3

Long-term outcomes of CMV disease treatment with valganciclovir versus IV ganciclovir in solid organ transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005133.PUB3

Effects of the intensity of immunosuppressive therapy on outcome of treatment for CMV disease in organ transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005133.PUB3

An assessment of herpesvirus co-infections in patients with CMV disease: correlation with clinical and virologic outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005133.PUB3

Impact of genetic polymorphisms in cytomegalovirus glycoprotein B on outcomes in solid-organ transplant recipients with cytomegalovirus disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005133.PUB3

Randomised comparison of ganciclovir and high-dose acyclovir for long-term cytomegalovirus prophylaxis in liver-transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005133.PUB3

Randomized controlled trial of oral ganciclovir versus oral acyclovir after induction with intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in cytomegalovirus-seropositive liver transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005133.PUB3

Randomized controlled trial of sequential intravenous and oral ganciclovir versus prolonged intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in high-risk cytomegalovirus-seronegative liver transplant recipients with cytom

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005133.PUB3

Viral factors influencing the outcome of human cytomegalovirus infection in liver transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005133.PUB3

Delayed-onset primary cytomegalovirus disease after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005133.PUB3

Delayed-onset primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005133.PUB3

New developments in the management of cytomegalovirus infection after solid organ transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005133.PUB3

Prophylaxis for CMV should not now replace pre-emptive therapy in solid organ transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005133.PUB3

Cytomegalovirus in transplantation - challenging the status quo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005133.PUB3

Prophylaxis for CMV should now replace pre-emptive therapy in solid organ transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005133.PUB3

Adequacy and reporting of allocation concealment: review of recent trials published in four general medical journals

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005133.PUB3

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005133.PUB3

Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: a systematic review of randomised controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005133.PUB3

Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005133.PUB3

Management of cytomegalovirus infection in solid organ transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005133.PUB3

Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005133.PUB3

Definitions of cytomegalovirus infection and disease in transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005133.PUB3

Effectiveness of deferred therapy with ganciclovir in renal allograft recipients with cytomegalovirus disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005133.PUB3

Preemptive versus prophylactic protocol to prevent cytomegalovirus infection after renal transplantation: a meta-analysis and systematic review of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005133.PUB3

Pre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005133.PUB3

Pre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005133.PUB3

Preemptive treatment for cytomegalovirus viremia to prevent cytomegalovirus disease in solid organ transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005133.PUB3

Oral Valganciclovir Is Noninferior to Intravenous Ganciclovir for the Treatment of Cytomegalovirus Disease in Solid Organ Transplant Recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005133.PUB3

Cytomegalovirus immune globulin after liver transplantation: a cost-effectiveness analysis 1

21 January 2018

1 reference

12 December 2020

Prevention of cytomegalovirus disease in renal allograft recipients

1 reference

12 December 2020

High-dose acyclovir prophylaxis reduces cytomegalovirus disease in liver transplant patients

1 reference

12 December 2020

Randomized trial of ganciclovir followed by high-dose oral acyclovir vs ganciclovir alone in the prevention of cytomegalovirus disease in pediatric liver transplant recipients: preliminary analysis

1 reference

12 December 2020

A Trial of Vidarabine for Cytomegalovirus Infection in Renal Transplant Patients

1 reference

12 December 2020

Failure of ganciclovir prophylaxis to prevent allograft reinfection following orthotopic liver transplantation for chronic hepatitis B infection

1 reference

12 December 2020

Effect of oral acyclovir or ganciclovir therapy after preemptive intravenous ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus seropositive renal and liver transplant recipients receiving antilymphocyte antibody therapy.

1 reference

12 December 2020

Cytomegalovirus resistance in solid organ transplant recipients treated with intravenous ganciclovir or oral valganciclovir

1 reference

12 December 2020

Efficacy of cytomegalovirus prophylaxis in renal retransplantation.

1 reference

12 December 2020

Control of cytomegalovirus-associated morbidity in renal transplant patients using intensive monitoring and either preemptive or deferred therapy

1 reference

12 December 2020

Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis

1 reference

12 December 2020

Ganciclovir for treatment of renal transplant-associated primary cytomegalovirus pneumonia

1 reference

12 December 2020

Prophylactic oral ganciclovir compared with deferred therapy for control of cytomegalovirus in renal transplant recipients

1 reference

12 December 2020

Cytomegalovirus infections in the immunocompromised transplant patient. Prevention of cytomegalovirus disease with oral acyclovir

1 reference

12 December 2020

Prophylaxis of cytomegalovirus infections with ganciclovir in kidney transplant recipients

1 reference

12 December 2020

A Randomized, Placebo-Controlled Trial of Oral Acyclovir for the Prevention of Cytomegalovirus Disease in Recipients of Renal Allografts

1 reference

12 December 2020

Evaluation of cytomegalovirus DNAaemia versus pp65-antigenaemia cutoff for guiding preemptive therapy in transplant recipients: a randomized study

1 reference

12 December 2020

Effect of prophylactic ganciclovir on cytomegalovirus infection in renal transplant recipients.

1 reference

12 December 2020

Cytomegalovirus immune globulin (CMVIG) prophylaxis is associated with increased survival after orthotopic liver transplantation. The Boston Center for Liver Transplantation CMVIG Study Group

1 reference

12 December 2020

Association of human herpesvirus 7 with cytomegalovirus disease in renal transplant recipients

1 reference

12 December 2020

Delayed occurrence of cytomegalovirus disease in organ transplant recipients receiving antiviral prophylaxis: are we winning the battle only to lose the war?

1 reference

12 December 2020

The economic impact of cytomegalovirus infection after liver transplantation

1 reference

12 December 2020

Open clinical trial with oral acyclovir for the prophylaxis of disease by Cytomegalovirus in low risk liver transplant recipients

1 reference

12 December 2020

Preemptive ganciclovir therapy in cytomegalovirus-seropositive renal transplants recipients

1 reference

12 December 2020

Efficacy of oral ganciclovir in prevention of cytomegalovirus infection in post-kidney transplant patients

1 reference

12 December 2020

Solid organ transplantation: results and implications of acyclovir use in liver transplants

1 reference

12 December 2020

Acyclovir in immunocompromised patients with cytomegalovirus disease. A controlled trial at one institution

1 reference

12 December 2020

Long-term oral ganciclovir prophylaxis for prevention of cytomegalovirus infection and disease in cytomegalovirus high-risk renal transplant recipients

1 reference

12 December 2020

Oral ganciclovir in the prevention of cytomegalovirus infection in postkidney transplant "CMV at risk" recipients: a controlled, comparative study of two regimens (750 mg Bid and 500 mg Bid)

1 reference

12 December 2020

Impact of high-dose oral acyclovir prophylaxis on cytomegalovirus (CMV) disease in CMV high-risk renal transplant recipients

1 reference

12 December 2020

A double-blind placebo-controlled trial of low-dose ganciclovir to prevent cytomegalovirus disease after heart transplantation

1 reference

12 December 2020

Cytomegalovirus in solid organ transplant recipients

1 reference

12 December 2020

A randomized prospective controlled trial of oral acyclovir versus oral ganciclovir for cytomegalovirus prophylaxis in high-risk kidney transplant recipients

1 reference

12 December 2020

Preemptive ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus antibody-positive renal transplant recipients. A randomized controlled trial

1 reference

12 December 2020

[Influence of HLA compatibility on cytomegalovirus infection in kidney transplantation]

1 reference

12 December 2020

High-dose acyclovir compared with short-course preemptive ganciclovir therapy to prevent cytomegalovirus disease in liver transplant recipients. A randomized trial

1 reference

12 December 2020

Immune globulin (GAMMAGARD) prophylaxis of CMV infections in patients undergoing organ transplantation and allogeneic bone marrow transplantation

1 reference

12 December 2020

Cytomegalovirus prophylaxis by ganciclovir followed by high-dose acyclovir in renal transplantation: a randomized, controlled trial

1 reference

12 December 2020

A comparative study of 500 mg BID and 250 mg BID of prophylactic oral ganciclovir in post-kidney transplant "CMV at risk" recipients

1 reference

12 December 2020

CYTOMEGALOVIRUS ANTIGENEMIA DIRECTED PRE-EMPTIVE PROPHYLAXIS WITH ORAL VERSUS I.V. GANCICLOVIR FOR THE PREVENTION OF CYTOMEGALOVIRUS DISEASE IN LIVER TRANSPLANT RECIPIENTS1

1 reference

12 December 2020

Randomized trial of daily versus three-times-weekly prophylactic ganciclovir after lung and heart-lung transplantation

1 reference

12 December 2020

Efficacy and cost effectiveness of oral ganciclovir in the prevention of cytomegalovirus disease after lung transplantation

1 reference

12 December 2020

Two grams daily of oral acyclovir reduces the incidence of cytomegalovirus disease in CMV-seropositive liver transplant recipients

1 reference

12 December 2020

The prevalence of human herpesvirus-7 in renal transplant recipients is unaffected by oral or intravenous ganciclovir

1 reference

12 December 2020

KDIGO clinical practice guideline for the care of kidney transplant recipients

1 reference

12 December 2020

Prophylactic treatment of cytomegalovirus primary infection with ganciclovir in renal transplant recipients

1 reference

12 December 2020

Prophylaxis of cytomegalovirus infection in liver transplantation: a randomized trial comparing a combination of ganciclovir and acyclovir to acyclovir. NIDDK Liver Transplantation Database

1 reference

12 December 2020

Controlled trial of prophylactic versus therapeutic use of ganciclovir after liver transplantation in adults

1 reference

12 December 2020

Prophylaxis of CMV disease by ganciclovir (DHPG) in seronegative recipients of renal allograft from seropositive donors

1 reference

12 December 2020

Valaciclovir prophylaxis of cytomegalovirus infection and disease in renal transplantation: an economic evaluation

1 reference

12 December 2020

Viral prophylaxis in hepatic transplantation: preliminary report of a randomized trial of acyclovir and gancyclovir.

1 reference

12 December 2020

Cytomegalovirus disease prophylaxis in seronegative recipients of kidneys from seropositive donors by combination of cytomegalovirus-hyperimmune globulin and low-dose acyclovir

1 reference

12 December 2020

Randomized controlled trial of acyclovir for the prevention of cytomegalovirus infection and disease in liver transplant recipients

1 reference

12 December 2020

Polymerase chain reaction-triggered preemptive or deferred therapy to control cytomegalovirus-associated morbidity and costs in renal transplant patients

1 reference

12 December 2020

Effective oral ganciclovir prophylaxis against cytomegalovirus disease in heart transplant recipients

1 reference

12 December 2020

Valacyclovir prophylaxis versus preemptive valganciclovir therapy to prevent cytomegalovirus disease after renal transplantation

1 reference

12 December 2020

Tacrolimus versus cyclosporine in primary simultaneous pancreas-kidney transplantation: preliminary results at 1 year of a large multicenter trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005133.PUB3

7 January 2021

inferred from DOI database lookup

Identifiers

DOI

10.1002/14651858.CD005133.PUB3

2 references

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

4819395

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23450558%20AND%20SRC:MED&resulttype=core&format=json

OpenCitations bibliographic resource ID

24 February 2020

4819395

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23450558%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

PubMed publication ID

23450558

1 reference